O(Reuters) - Optimer Pharmaceuticals Inc (OPTR.O) said it was exploring a possible sale of the company among a full range of alternatives and that Chairman Henry McKinnell would act as chief executive for the duration of the review process.
Optimer shares were up 11.6 percent at $11.95 in premarket trading.
McKinnell will replace Pedro Lichtinger, who has been at the helm since 2010.